The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately one third of patients
with acute myeloid leukemia (AML), either by internal tandem duplications (FLT3-ITD), or by …

Midostaurin was recently approved by the US Food and Drug Administration for the
treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive …

Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …

In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …

The spectrum of somatic alterations in hematologic malignancies includes substitutions,
insertions/deletions (indels), copy number alterations (CNAs), and a wide range of gene …

Purpose To analyze the frequency and associations with prognostic markers and outcome of
mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo …

Purpose The Microarray Innovations in Leukemia study assessed the clinical utility of gene
expression profiling as a single test to subtype leukemias into conventional categories of …

Advances in the understanding of the molecular basis for acute myeloid leukemia (AML)
have generated new potential targets for treatment. Fms-like tyrosine kinase 3 (FLT3) is one …

The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in 25-30% of patients with acute
myeloid leukemia (AML). Because of the poor prognosis associated with FLT3-internal …

Mutations within the FMS-like tyrosine kinase 3 (FLT3) gene on chromosome 13q12 have
been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of …